Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

MedicalXpress | يول 07, 2026

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating them with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.